Trial Profile
A phase 1 study of pembrolizumab in patients with melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Aug 2015
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 Aug 2015 New trial record
- 22 Apr 2015 Peliminary results presented at the 106th Annual Meeting of the American Association for Cancer Research.